The Federal Circuit Addresses Patent Eligibility of Methods of Treatment For First Time Post-Mayo

by K&L Gates LLP
Contact

K&L Gates LLP

Introduction

On April 13, 2018, the U.S. Court of Appeals for the Federal Circuit in Vanda Pharmaceuticals affirmed a district court decision regarding patent eligibility under 35 U.S.C. § 101 of a method of treatment. [1] In Vanda, the Federal Circuit applied the eligibility test set forth by the U.S. Supreme Court in Mayo v. Prometheus, [2] and the majority held that the claimed therapeutic method was patent eligible subject matter. [3] This holding of eligibility by the majority, along with the reasoning behind the holding, provides noteworthy insights relevant to patent prosecution and patent litigation, particularly in view of the previous absence of Federal Circuit decisions directly related to eligibility of therapeutic methods.

The Patent at Issue

As noted by the Federal Circuit, the patent at issue [4] “relates to a method of treating schizophrenia patients with iloperidone wherein the dosage range is based on the patient’s genotype.” The patent eligibility of the claimed therapeutic method was challenged on the alleged basis that the claims were directed to a natural law or phenomenon and thus indistinguishable from the invalid claims in Myriad [5] and Mayo. [6] The Federal Circuit characterized the first independent claim as a representative claim, and this claim recites the following:

A method for treating a patient with iloperidone, wherein the patient is suffering from schizophrenia, the method comprising the steps of:

determining whether the patient is a CYP2D6 poor metabolizer by: obtaining or having obtained a biological sample from the patient; and performing or having performed a genotyping assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and

if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day, wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.

The Majority Opinion

The patent eligibility of the claimed therapeutic method was specifically challenged on the alleged basis that the claimed method is directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QT prolongation and “adds nothing inventive” to those natural laws and phenomena. However, the majority of the Federal Circuit disagreed, in particular asserting that the inventors indeed recognized these natural relationships but nevertheless claimed a patent eligible application of the relationships.

In making this determination, the Federal Circuit applied the two-step eligibility test set forth by the U.S. Supreme Court in Mayo: The first step requires determining whether the claims are “directed” to a patent-ineligible concept. The second step is undertaken only if the first step is not fulfilled, and requires determination of whether the claim includes an inventive concept, i.e., an element or combination of elements that ensures that the patent would be significantly more than a patent merely upon the ineligible concept itself.

The majority here in Vanda noted that the claims require a treating doctor to administer iloperidone in one of two doses, depending on the result of a genotyping assay. The specificity of the claim language was also emphasized by the majority: “the claims here are directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome.” Furthermore, the specification highlights the significance of the specific dosages by disclosing that the recited doses are safer for patients. Therefore, according to the majority, the claims are directed to a new way of using an existing drug and not merely the underlying natural relationship. As a result, the majority held that the claims were not directed to a patent ineligible concept and thus satisfied step one of the two-step eligibility test from Mayo such that the step two analysis was not needed.

Notably, the majority clarified its understanding of Mayo and the claims held invalid in that case. For example, the majority stated that the claims in Mayo were not directed to a novel method of treating a disease but instead were directed to a diagnostic method based on the natural relationships, e.g., the claim as a whole was not directed to the application of a drug to treat a particular disease.

The majority also relied upon the recent decision CellzDirect [7] as support for the eligibility of the claimed therapeutic method. In this regard, the majority noted that the holding in that case was that a “method of producing a desired preparation of multi-cryopreserved hepatocytes” was eligible because its end result was not merely an observation or detection, and the natural ability of the material to undergo the process did not make the claim directed to a natural law.

Finally, the majority characterized its holding that the claimed therapeutic methods were patent eligible as consistent with Myriad. [8] For example, in Myriad, the U.S. Supreme Court found that a naturally occurring DNA segment is a product of nature and, even if isolated, not patent eligible; but the U.S. Supreme Court also explicitly stated that method claims and new applications of knowledge about particular genes were “not implicated by [its] decision.”

The Dissent

The dissent in Vanda asserted that the claims were directed to a law of nature and thus ineligible. In particular, the dissent agreed with the majority that the claims at issue do not solely state a law of nature, but nevertheless the dissent asserted that the claims simply direct the relevant audience to apply the law of nature. Further in this regard, the dissent characterized the claims as mere instructions directing the relevant audience to apply the natural law in a routine and conventional manner, which Mayo classifies as patent ineligible.

Consequences for Patent Practice

The presence of the dissent in the Vanda opinion suggests that the patent eligibility of therapeutic methods could continue to be refined as these inventions are considered in subsequent decisions in the Federal Circuit and perhaps even the U.S. Supreme Court. Indeed, it is unlikely that therapeutic methods will be classified as per se patent eligible, especially when an aspect of the claim is diagnosis of the patient. However, the holding of the majority in Vanda indicates that claims reciting treatment “for specific patients using a specific compound at specific doses to achieve a specific outcome” have a strong position regarding patent eligibility.

Furthermore, the statements of the majority in Vanda distinguishing the claims at issue (and also those of CellzDirect) from those found ineligible in Mayo are insightful. In this regard, the majority in Vanda emphasized that the “end result” of the claims in Mayo was simply observation or detection, even though the claimed method there began with an “administering” step. To the contrary, the methods of Vanda and CellzDirect end with a tangible step that could not be conducted merely mentally. Accordingly, in addition to the specificity of an “administering” step, the role of the “administering” step may be critical for eligibility, i.e., whether it is the basis for mere observation or detection or instead a tangible application of the alleged natural law.

Moreover, the holding of the majority in Vanda suggests that disclosures in the specification regarding the benefits of the actual treatment, e.g., the administering step and its claim limitations, should be considered when determining whether the claim is directed to a patent ineligible natural law or instead an eligible application of the natural law.

Conclusion

The Federal Circuit’s holding in Vanda regarding patent eligibility of claims directed to a method of treatment makes several points that should be considered by practitioners analyzing the patentability or validity of such an invention. These points may be refined further as other cases tackle the issue, but the Federal Circuit’s application of the Mayo eligibility test to a therapeutic method in Vanda provides some clarity that was lacking in view of an absence of decisions directly addressing these types of claims.


[1] Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, Nos. 2016-2707, 2016‑2708 (Fed. Cir. Apr. 13, 2018).

[2] Mayo v. Prometheus, 132 S. Ct. 1289, 1294(2012).

[3] Vanda Pharm. Inc. v. Roxane Labs., Inc., 203 F. Supp. 3d 412 (D. Del. 2016).

[4] U.S. Patent No. 8,586,610 entitled “Methods for the administration of iloperidone.”

[5] Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).

[6] Endnote 2

[7] Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042, 1050 (Fed. Cir. 2016).

[8] Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2119-2120 (2013).

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© K&L Gates LLP | Attorney Advertising

Written by:

K&L Gates LLP
Contact
more
less

K&L Gates LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.